Q BioMed Statistics
Total Valuation
Q BioMed has a market cap or net worth of 145. The enterprise value is 9.25 million.
| Market Cap | 145 |
| Enterprise Value | 9.25M |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Q BioMed has 145.09 million shares outstanding.
| Shares Outstanding | 145.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +52.30% |
| Owned by Insiders (%) | 2.90% |
| Owned by Institutions (%) | n/a |
| Float | 140.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.85 |
| EV / Sales | 44.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -85.13% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.00% in the last 52 weeks. The beta is 81.20, so Q BioMed's price volatility has been higher than the market average.
| Beta (5Y) | 81.20 |
| 52-Week Price Change | +25.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 55.38 |
| Average Volume (20 Days) | 5,387 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.68 |
Income Statement
In the last 12 months, Q BioMed had revenue of 209,293 and -1.91 million in losses. Loss per share was -0.03.
| Revenue | 209,293 |
| Gross Profit | -12,602 |
| Operating Income | -2.73M |
| Pretax Income | -485,082 |
| Net Income | -1.91M |
| EBITDA | -2.68M |
| EBIT | -2.73M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 23,173 in cash and 4.08 million in debt, giving a net cash position of -4.06 million or -0.03 per share.
| Cash & Cash Equivalents | 23,173 |
| Total Debt | 4.08M |
| Net Cash | -4.06M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -6.44M |
| Book Value Per Share | -0.09 |
| Working Capital | -9.87M |
Cash Flow
| Operating Cash Flow | 2.18M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -6.02%, with operating and profit margins of -1,302.56% and -231.77%.
| Gross Margin | -6.02% |
| Operating Margin | -1,302.56% |
| Pretax Margin | -231.77% |
| Profit Margin | -231.77% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Q BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -130.36% |
| Shareholder Yield | -130.36% |
| Earnings Yield | -3,091,800.00% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 7, 2015. It was a forward split with a ratio of 2.5.
| Last Split Date | Aug 7, 2015 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
Q BioMed has an Altman Z-Score of -33.38. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.38 |
| Piotroski F-Score | n/a |